Dangerous Deception: Hiding the Evidence of Adverse Drug Effects_NEJM
FDA's slip-shod approval of defective, harmful drugs, accompanied by rubber stampped endorsements by compromised FDA advisory committees may be reaching a boiling point.
-
-
Psychiatry News: High Cost of Nondisclosure
Legislation is needed to ensure that conflicts of interest rules in medicine are enforced. One method for reigning in the abuse is to prohibit government grant awards to any researcher who violates financial conflict of interest rules.
-
Scientific Fraud & Corruption on Both sides of Atlantic: Merck / Proctor & Gamble
Scientific Fraud & Corruption on Both sides of Atlantic: Merck / Proctor & Gamble Sun, 11 Dec 2005 Two major cases of medical research fraud on each side of the Atlantic involve evidence of fraud and data tampering by pharmaceutical company giants. Both cases provide insight into the way in…
-
ADHD drug Cylert withdrawn from market due to Liver Toxicity
ADHD drug – Cylert withdrawn from market due to Liver Toxicity, a Major Risk of Psychotropic Drugs Tue, October 25, 2005 The FDA announced that another drug prescribed for ADHD–Cylert–was removed from the US market for safety reasons. On September 25, 2005, the Associated Press reported: “Eli Lilly said it…
-
When Doctors Go to Class, Industry Often Foots the Bill – WSJ
When Doctors Go to Class, Industry Often Foots the Bill – WSJ Fri, 6 Dec 2002 A front page article in The Wall Street Journal by Scott Hensley sheds further light on the corruption of medical ethics by focusing on a drug marketing ploy that is promoted as “continuing medical…
-
Not-So-Public-Relations: Drug Industry & Bioethics – is it casuistry or sophistry?
Not-So-Public-Relations: Drug Industry & Bioethics – is it casuistry or sophistry? Fri, 19 Dec 2003 Carl Elliott is a clear eyed academic who teaches bioethics at the University of Minnesota . He is currently a visiting associate professor at School of Social Sciences at the Institute for Advanced Study at Princeton….
-
Public Comments Dr. William J. Bicknell Prof. Int’l Health, Boston U
Public Comments: Dr. William J. Bicknell, Professor of International Health, Boston University Dear Dr. Ball: I am submitting these comments in reference to the announcement published in the Federal Register, Vol. 67, No. 211, Thursday, October 31, 2002 regarding the Solicitation of Public Review and Comment on Research Protocol: A…
-
Psychopharmacology in Turmoil: David Healy, MD Presentation Columbia + Debate Dr. Joseph Coyne, Ph.D
Psychopharmacology in Turmoil: David Healy, MD Presentation Columbia + Debate Dr. Joseph Coyne, Ph.D Fri, 9 Dec 2005 Recent reports describing a determined effort to pathologize US infants and toddlers who are being declared to suffer from “severe mental disorders”–the latest, most aggressively marketed diagnosis for children is Bipolar disorder,…
-
Harvard Study: Multivitamins Effective in Thwarting AIDS progress
Harvard Study: Multivitamins Effective in Thwarting AIDS progress Thu, 1 Jul 2004 A report in the New England Journal of Medicine may be the first serious challenge to the current accepted treatment of people infected with the HIV-virus. Those expensive and toxic cocktails of AIDS drugs may not be the…
-
Minnesota initiative: Compulsory newborn congenital testing
Minnesota initiative: Compulsory newborn congenital testing Mon, 24 Mar 2003 The Minnesota House Health and Human Services Policy Committee will vote tomorrow on a law requiring the screening of every newborn baby to ascertain who may have a congenital disorder. It is important to note that this “public health” initiative…
-
At FDA, Graham is still the whistle-blower – USA Today
At FDA, Graham is still the whistle-blower – USA Today Thu, 17 Nov 2005 On Nov. 18, 2004, Dr. David Graham, FDA’s associate director for science and medicine, blew the whistle in testimony before the Senate Finance Committee, on FDA’s “profound regulatory failure” to protect the public against lethal prescription…
-
Statin-Cholesterol Guidelines–Industry influenced?
Statin-Cholesterol Guidelines–Industry influenced? Wed, 14 Jul 2004 Scientific journal editors are scrambling about how to react to bad publicity emanating from public disclosure that the scientific reports they have published are likely to be biased because the authors’ had financial ties to the companies whose drugs / devices they report…